ArticleTranslational cancer research2026
Association of METTL14 expression with prognosis and immunotherapy in breast cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methyltransferase-like 14 (METTL14) is recognized as a key factor in the advancement and progression of breast cancer (BC). While its involvement in this context is acknowledged, many aspects of METTL14's functions remain unclear. We aimed to explore the function and potential mechanism of METTL14 in BC. Methods: The level of METTL14 in BC cell lines and tissues was evaluated using quantitative real-time polymerase chain reaction, immunohistochemistry, and western blotting methods. The cell counting kit-8 (CCK-8) assay, wound healing assay, and transwell chamber assay were employed to investigate the biological functions of METTL14 in BC. The relationship between immune characteristics and METTL14 was analyzed using the Tumor Immune Estimation Resource (TIMER) and Tumor-Immune System Interaction Database (TISIDB). The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm was used to predict immunotherapy response of BC patients. Multiplex immunofluorescence (mIF) was used to evaluate the expression of eight candidate markers of immune cell subsets and checkpoints in BC samples. Furthermore, a Kaplan-Meier survival analysis was performed to assess the prognostic significance of METTL14 in BC. Results: Our study revealed a significant downregulation of METTL14 in BC tissues. The reduced expression of METTL14 was found to be associated with tumor progression, unfavorable recurrence-free survival (RFS) outcomes, and advanced tumor stages. Furthermore, METTL14 expression exhibited a positive correlation with the abundance of CD8 Conclusions: METTL14 demonstrates significant predictive value regarding prognosis in BC. The METTL14 has the potential to serve as a predictive biomarker and a promising target for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.